In MINDED, the integration of robot-based and personalized interventions for autism spectrum disorder has marked a shift from generic therapies to more tailored approaches, enhancing social cognition and therapeutic outcomes. Innovations in robot design, such as addressing sensory sensitivities and motor sounds, along with the development of adaptive strategies for rehabilitation, have pushed the boundaries of personalized medicine and adaptive technology. Similarly, RNA research has helped uncover the dual role of LINE-1 elements providing novel insights into cortical development and gene regulation, that could in a near future pave the way to new molecular therapies. In the realm of drug delivery systems, the development of shape-defined microparticles for the sustained release of small molecules has demonstrated the ability to alleviate conditions associated with neurodevelopmental disorders (NDD). Although these advancements offer a new understanding and better ability to treat neurodevelopmental disorders, more work is needed to identify and modulate the expression of genes involved in specific disorders.
These advancements can lead to an improved quality of life, reduced healthcare costs, and broader accessibility to high-quality interventions. They could also offer potential economic benefits through the incorporation and development of new biotech start-ups stemming from the MINDED discoveries.
The MINDED project has trained research fellows across three major disciplines: nanomedicine, aimed at delivering therapeutic and imaging agents for NeuroDevelopmental Disorders (NDD) through multifunctional nanoconstructs; molecular neuroscience, focusing on identifying genes related to NDD and synthesizing RNA molecules to restore their expression; and cognitive neuroscience robotics, which developed novel diagnostic and therapeutic strategies using assistive robotics for NDDs.
The MINDED fellows made significant impacts in three key areas. First, they demonstrated that robot-assisted interventions improved social skills in educational and therapeutic settings for children with autism. Personalized robot training, tailored to the different sensory abilities of patients, yielded better therapeutic outcomes. Second, research on RNA highlighted the role of LINE-1 elements in brain development, linking their disruptions to NDD. Finally, MINDED fellows developed microPlates, a novel drug delivery system for the sustained release of small molecules, enhancing cognitive function in preclinical models while utilizing machine learning to optimize the properties of these systems. This work has been documented in over 60 scientific manuscripts published under the program and an equally large number of presentations at international and national conferences, as well as at dissemination events organized for the general public.
While the advancements presented by the MINDED fellows have enhanced our understanding and ability to treat NDDs, additional fundamental steps are needed for the effective integration of these disciplines and the development of successful therapies. The MINDED program has provided the fellows with the intellectual tools and knowledge to continue this research independently in various settings, both academic and industrial.
